New Lynx Dx Urine Test Outperforms MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
Lynx Dx announced the validation of MyProstateScore 2.0 – Active Surveillance (MPS2-AS), a non-invasive urine test designed to guide biopsy decisions for men with Grade Group 1 prostate cancer. In a clinical validation study published in The Journal of Urology, MPS2-AS outperformed multiparametric MRI in determining the need for biopsies during active surveillance, potentially avoiding up to 64% of unnecessary procedures. The test exhibited high sensitivity and negative predictive value for detecting upgrading in prostate cancer.
Clinical Validation Study Supports a Non-Invasive Monitoring Approach Where MPS2-AS Accurately Guides the Need for Surveillance Biopsies ANN ARBOR, Mich., May 5, 2026 /PRNewswire/ — Lynx Dx, a leader in innovative diagnostic solutions, announced today the validation of MyProstateScore…